Please login to the form below

Not currently logged in
Email:
Password:

Excellence in Rare Diseases and Orphan Drugs

Sponsored by

Back to Results


Finalist

‘Make The Connection’ - Helping Paediatricians Join the Dots to Recognise MPS I

by Sanofi Genzyme
with support from Health IQ, Republic M! and Havas Life Medicom


Summary of work

Mucopolysaccharidosis Type I (MPS I) has an overall prevalence of 1:100,0001 meaning that any one paediatrician is unlikely to see a patient during his/her career. It is a progressive, debilitating, life- threatening disease which, if diagnosed early with a simple urine test, can be effectively managed at specialist centres to give patients better outcomes. We needed a new approach, without an in-house sales team, to raise awareness of MPS I. Analysis of RWD, conducted in line with Information Governance (IG) rules, outlined MPS I prevalence at a suitable regional level and a separate segmentation exercise provided priority lists of paediatric specialities who may potentially see MPS I children in their clinics. To execute the final part of the campaign, a third-party remote detailing agency contacted physicians, from the priority lists provided, to educate them on the condition, give information on how to test and diagnose MPS I and refer suspected cases to specialist treatment centres for follow-up and management.

1. Laraway S, Breen C, Mercer J et al Molecular Genetics and Metabolism 2013;109:315-316

Judges' comments

Sanofi Genzyme showed real precision marketing pinpoint of understanding. They took a creative analytical approach and had real, demonstrable outcomes. We liked seeing the re-work of the data and the smart working.



Highly commended

Delivering Innovation in a Rare Disease Launch - By Amicus Therapeutics UK Ltd


Finalists

‘Make The Connection’ - Helping Paediatricians Join the Dots to Recognise MPS I - by Sanofi Genzyme
with support from Health IQ, Republic M! and Havas Life Medicom